Venus Medtech (Hangzhou) Class H Receivables

Venus Medtech (Hangzhou) Class H (VMTHF) currently reports a receivables of $200M as of June 2026. That compares with $320M in the prior-year period — down 35.9% year over year. Use the charts on this page to explore Venus Medtech (Hangzhou) Class H's receivables history and peer comparisons.

Venus Medtech (Hangzhou) Class H's receivables decreased from $320M to $200M — a 35.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Venus Medtech (Hangzhou) Class H reported $200M in receivables as of June 2026. That compares with $320M in the prior-year period — down 35.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $200M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Venus Medtech (Hangzhou) Class H, and consider following VMTHF for alerts when major investors trade the stock.